Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin: First interim Safety and Efficacy Results from TOPAZ-I
Author
Schott, Eckart
Agarwal, Kosh
Dumas, Emily O.
Gaeta, Giovanni B.
Lee, Sam
Streinu-Cercel, Adrian
Andrade, Raul J.
Perez, Alma M.
George, Jacob
Bakulin, Igor G.
Marinho, Rui T.
Charafeddine, Mariem
Liu, Li
Pilot-Matias, Tami
Howieson, Kevin
Co, Melannie
Cohen, Daniel E.
Zoulim, Fabien
Ozaras, Resat
Metadata
Show full item recordCollections
- Bildiri [64839]